 Adjunctive anti-platelet therapy is a critical factor in optimizing long term DES safety. Despite established guidelines that recommend 6-12 months dual antiplatelet therapy, patients with DES implants frequently stop taking their medication early. Consequently, XIENCE V EECSS India Post-marketing Single-Arm Study XIENCE V India follow-up will document patient adherence and persistence with adjunctive antiplatelet drug therapy at several time points throughout the study. 